Liudmyla Ivanivna Vakulenko

Prof. Dr. Liudmyla Ivanivna Vakulenko

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
Dmytro Dmitrii IvanovDmytro Dmitrii Ivanov
Dmytro Dmitrii Ivanov
LWLutz T Weber
Lutz T Weber
ELElena Levtchenko
Elena Levtchenko
LVLiudmyla Ivanivna Vakulenko
Liudmyla Ivanivna Vakulenko
Mariia IvanovaMariia Ivanova
Mariia Ivanova
NBNinel Boiko
Ninel Boiko
Background: Steroid-sensitive nephrotic syndrome (SSNS) and steroid-resistant nephrotic syndrome (SRNS) significantly affect children’s quality of life. There are frequent relapses in SSNS and progression in SRNS. IPNA guidelines suggest that monoclonal antibodies like rituximab (RTX) are promising treatments. Objective: This study aims to evaluate the long-term efficacy and safety of rituximab administration in children with SSNS, encompassing FRNS and SDNS, and SRNS over a two-year follow-up period, facilitating individualized management. Methods: We conducted an open-label, multicenter, randomized, and patient-oriented study (RICHNESS), involving children aged 3–18 with SRNS (18) and SSNS (11) undergoing 2 years continuous RTX therapy. The primary outcome was complete/partial remission (CR/PR), as defined by IPNA/KDIGO guidelines, at 6, 12, 18, and 24 months on RTX; secondary outcomes included adverse events. Key endpoints included the estimated glomerular filtration rate (eGFR), the albumin-to-creatinine ratio (ACR), CD20 levels, IgG levels, and the incidence of infections. Kidney biopsies were performed in 94% of SRNS patients. RTX was administered every 6–9 months, depending on CD20 levels, IgG levels, and the presence of infections. The eGFR and ACR were assessed every 6 months. Results: Some 31 children were selected for RTX treatment. Overall, 2 experienced severe allergic reactions, leading to their exclusion from the final analysis of 29 children. In the SSNS group, all children achieved and maintained complete remission within 2 years. Remission rates in the SRNS group ranged from 39% (RR 0.78; 95% CI: 16.4–61.4%, NNT 9) at the 6th month to 72% (RR 1.44; 95% CI: 51.5–92.9%) over the 2-year follow-up period due to continuous RTX therapy. The median duration of RTX use was 26.1 months, with a median cumulative dose of 1820 mg/m2. Adverse reactions and complications were presented by mild infusion-related reactions in 3 children (10.3%), severe allergic reactions in 2 children (6.2%), hypogammaglobulinemia in 7 children (24%), infections in 3 children (10.3%), severe destructive pneumonia in 1 child, recurrent respiratory infections in 2 children, and neutropenia in 1 child (3.44%). Conclusions: RTX was tolerated well, and proved highly effective as a steroid-sparing agent, offering potential in terms of stopping relapses and minimizing steroid-related side effects. It also demonstrated efficacy in slowing progression in SRNS, indicating potential for use in ACR reduction and renal function restoration, but requires careful use given potential severe allergic reactions and infectious complications. Further studies should focus on long-term cost-effectiveness and deferred side effects.

13 July 2022 in KIDNEYS
Verified
Journal Article
Open access
PDF file
LVLiudmyla Ivanivna Vakulenko
Liudmyla Ivanivna Vakulenko
OLO.M. Lytvynova
O.M. Lytvynova
IPI.V. Posmitjuha
I.V. Posmitjuha
Background. High recurrence rates of nephrotic syndrome in children and consequences in the form of steroid dependence and a high risk of side effects from corticosteroids as a result involve immunosuppressive steroid-preserving agents that would increase long-term remission. Rituximab, a chimeric anti-CD20 monoclonal antibody that inhibits CD20-mediated B-cell proliferation and differentiation, has been identified as a possible alternative treatment. The purpose of the study — to estimate the efficacy and safety of treatment recurrence of nephrotic syndrome in children using rituximab like we did it on three clinical cases. Materials and methods. The experience of rituximab in children was analyzed according to the databases of Scopus, Web of Science, MedLine, The Cochrane Library, EMBASE, Global Health and our own study of the treatment of three children with steroid-sensitive nephrotic syndrome was presented. Results. Treatment of nephrotic syndrome in three children who are 5 to 7 years with rituximab was conducted. One child had a second recurrence, two children had a first recurrence. The previous episode of nephrotic syndrome in all children was treated according to the recommendations of KDIGO 2021. All patients received rituximab (two intravenous injections two weeks apart) at a dose of 15 mg/kg for 5–6 hours with prior administration of methylprednisolone at a dose of 7–10 mg/kg. One child had side effects to the first administration of rituximab in the form of hypotension 70/40 and tachycardia 116–118. Reducing the speed of administration helped to eliminate side effects. The next injection in two weeks the child endured well. The other two children had no side effects to both rituximab injections. Moreover after 1 month of rituximab administration was without side effects or hematological changes. The next administration of ritu­ximab is scheduled in 6 months after the last administration with prior control of CD20 level. Conclusions. In general a review of studies of rituximab confirms the high efficacy of the medication in nephrotic syndrome in children and the requirement for long-term evaluation. Rituximab can be considered as a first-line treatment for recurrence of nephrotic syndrome, including in resource-limited settings. Our own experience with rituximab in recurrent nephrotic syndrome has revealed slight short-term side effects.

28 May 2022 in CHILD`S HEALTH
Verified
Journal Article
Open access
PDF file
OOO.YU. Obolonska
O.YU. Obolonska
LVLiudmyla Ivanivna Vakulenko
Liudmyla Ivanivna Vakulenko
LBL.P. Badogina
L.P. Badogina
OOO.I. Obolonskyi
O.I. Obolonskyi
ILI.A. Likhachova
I.A. Likhachova
OKO.V. Kovryga
O.V. Kovryga
Background. Retinopathy of prematurity is one of the disabling conditions in premature babies. Despite the fact that the main predictors for the development of retinopathy of prematurity are known, the factors that can potentially cause it require further study. The purpose was to determine risk factors for the development of retinopathy in premature newborns for better control. Materials and methods. A retrospective analysis of 50 medical records of inpatient premature babies with a gestational age of 28–34 weeks and the medical charts of their mothers was carried out. Two groups were distinguished: the first one — 29 children with retinopathy, the second one — 21 patient without retinopathy. Results. The vast majority of children — 38 (76.0 %) were born at a gestational age of 28–31 weeks. Differences between groups were not significant. The analysis showed that 14 (48.3 %) premature children were diagnosed with stage I retinopathy, 6 (20.7 %) — with stage II, 5 (17.2 %) — with stage ІІІ and 4 (13.8 %) — with stage IV. The most influential risk factors for the development of retinopathy of prematurity were identified. The presence of retinopathy significantly correlated with gestational age of less than 34 weeks (ρ = 0.64, p < 0.001), need for oxygen subsidy ≥ 40 % (ρ = 0.59, р < 0.001), development of bronchopulmonary dysplasia (ρ = 0.34, р < 0.01), sepsis (ρ = 0.59, р < 0.001), intraventricular hemorrhages (ρ = 0.56, р < 0.001). It was also found that the presence of a burdened maternal history in the form of chronic foci of infection and chorioamnionitis is a significant risk factor for the development of retinopathy (ρ = 0.56, р < 0.001). Moreover, the presence of an infection in the mother increased the risk of retinopathy stage III–IV in a child by 3.8 times (p < 0.05), and stage I–II retinopathy — by 5 times. With a combination of chorioamnionitis and chronic foci of infection, the risk of developing severe retinopathy was almost 95 % (р < 0.007). Conclusions. Burdened maternal history in the form of chronic foci of infection and/or choriamnionitis is an important risk factor for the development of retinopathy in children. Chorioamnionitis is a predictor of severe retinopathy. Treatment of chronic foci of infection in pregnant women should be considered as a mandatory measure to prevent retinopathy in premature newborns.

30 June 2019 in PERINATOLOGIYA I PEDIATRIYA
Verified
Journal Article
Closed access
ОAО.YE. Abaturov
О.YE. Abaturov
LVLiudmyla Ivanivna Vakulenko
Liudmyla Ivanivna Vakulenko

30 June 2023 in CHILD`S HEALTH
Verified
Journal Article
Open access
PDF file
LVLiudmyla Ivanivna Vakulenko
Liudmyla Ivanivna Vakulenko
OOO. Obolonska
O. Obolonska
ONOleh Nekhanevych
Oleh Nekhanevych
VGV. Golyk
V. Golyk
TOT. Obolonska
T. Obolonska
Background. The adverse social situation in Ukraine and an increase in the number of injured children lead to a burden on trauma departments and rehabilitation centers. Looking for simple methods to help detect violations of compensatory mechanisms, one of which is the centralization of blood circulation, and impaired perfusion at the microcirculatory periphery level is of great current relevance. Materials and methods. A comprehensive clinical and functional examinations were applied to 44 children aged 10–15 years, 21 of them had home-related upper extremity fractures (main group), 23 otherwise healthy children served as the control group. All the children underwent the Box and Block Test (BBT), and the perfusion index (PI) from the extremities was recorded. Results. The BBT performance was characterized by a 1.6-fold decrease (p < 0.05) in the affected extremity of children aged 10–15 years under the rehabilitation treatment compared to that of the non-dominant extremity in healthy children and a 1.3-fold decrease (p < 0.05) in the healthy extremity compared to the dominant one. PI decreased to 2.52 ± 0.58 at rest in the main group children who underwent upper extremity rehabilitation treatment for injuries compared to 3.49 ± 0.34 (p < 0.05) in healthy children. PI reduced to 1.57 ± 0.56 in injured children at exercise loads versus 2.93 ± 0.91 (p < 0.05) in healthy children. The dynamics of recovery also differed and amounted to 2.82 ± 0.45 in the main group versus 4.00 ± 0.64 in the control group. Children with PI up to 1.5 ± 0.4 had significantly lower BBT scores at the beginning of exercise training. PI reduction to less than 1.5 allowed predicting a decrease in muscle functions, delayed wound healing, and the need for analgesia. With an increase in PI to 2.40 ± 0.54 during exercise training, children performed BBT better, while those who had a decrease in perfusion up to 0.98 ± 0.20 performed it twice as slowly (p < 0.05). As a study result, an association between the physical exercise load, changes in PI and BBT has been revealed. Conclusions. BBT scores were characterized by a 1.6-, 2.0- and 1.8-fold (p < 0.05) reduction during the first, second and third measurements, respectively, compared to those of healthy children. Characteristic feature of perfusion index was a statistically significant decrease before and during exercise training as well as slow dynamics of recovery. The correlations between perfusion index and BBT have proven the association of the rehabilitation processes and blood flow restoration.

20 September 2024 in KIDNEYS
Verified
Journal Article
Open access
PDF file
LVLiudmyla Ivanivna Vakulenko
Liudmyla Ivanivna Vakulenko
Background. X-linked hypophosphatemia is the most common form of hereditary vitamin D-resistant rickets. Today, there is a late diagnosis, later treatment start and a significant deterioration in the quality of life of patients with X-linked hypophosphatemia. The aim of the study is to use a clinical case as an example in order to draw attention to the problem of X-linked hypophosphatemia and consider traditional and novel approaches to the diagnosis and the­rapy. Materials and methods. We analyzed a family case of ­X-linked hypophosphatemia in a 4-year-old boy. Results. Based on the analysis of a family case, modern approaches to clinical, laboratory and instrumental diagnosis recommended by international clinical guidelines for the diagnosis and treatment of X-linked hypophosphatemia are considered. The causes for late diagnosis, advantages and disadvantages of traditional therapy are analyzed. Treatment was adjusted including phosphate and active vitamin D preparations, ta­king into account international clinical guidelines. The latest data are presented on the treatment of X-linked hypophosphatemia with biological therapy using burosumab. The results of short-term stu­dies on the efficacy and safety of burosumab in children and adults are described. Conclusions. X-linked hypophosphatemia is a complex hereditary tubulopathy requiring timely diagnosis, treatment and thorough patient management by a multidisciplinary team of doctors. Once X-linked hypophosphatemia is suspected, a clinical, laboratory and instrumental examination of a patient should be carried out in accordance with international recommendations. Although traditional therapy has limited therapeutic efficacy and side effects, its early initiation is associated with better outcomes. A significant progress in the treatment of hypophosphatemic vitamin D-resistant rickets was achieved due to the biological therapy with burosumab aimed at its pathophysiological mechanisms. The profile of burosumab effects allows this therapy to be considered life-saving.